Rate Of Intracerebral Hemorrhage Research Articles

Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials.

Since its approval, the use of alteplase had been limited to patients aged ≤80 years. TESPI trial had been designed to evaluate whether alteplase treatment within 3 h in patients with acute ischemic stroke aged >80 years resulted in favorable benefit/risk ratio compared with standard care. The meta-analysis of randomized controlled trials was updated to put findings in the context of all available evidence. TESPI was a multicenter, open-label with blinded outcome evaluation, randomized, controlled trial. Main clinical endpoints were 90-day favorable functional outcome (mRS score 0-2) and mortality and symptomatic intracerebral hemorrhage. The trial was prematurely terminated for ethical reasons after publication of IST-3 trial which provided evidence of treatment benefit in elderly. Of the planned 600 patients, 191 (88 assigned to alteplase) were enrolled. Overall, 24/83 (28.9%) alteplase patients had a favorable outcome compared to 22/95 (23.2%) controls (non-significant absolute difference of 5.7% for alteplase; OR 1.35, 95% CI 0.69-2.64, P = 0.381). Rates of death were non-significantly lower in the alteplase patients (18.1% vs. 26.5%); rates of symptomatic intracerebral hemorrhage were similar between the two groups (5.9% vs. 5.1%). The updated meta-analysis showed consistent results with prior estimates and add weights. The effects of alteplase observed in this interrupted trial did not reach statistical significance, probably for the small numbers, but are consistent with and add weight to the sum total of the randomized evidence demonstrating that alteplase is beneficial in patients with acute ischemic stroke aged over 80 years, particularly if given within 3 h.

Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke

Background and Purpose: The timely administration of thrombolytic therapy for acute ischemic stroke has been associated with good functional outcomes. Current guidelines recommend alteplase administration within 60 minutes in 75% of eligible patients and within 45 minutes in 50% of patients. There is limited evidence guiding these measures and their effect on outcomes. We report a single-center, retrospective assessment of the safety and efficacy of alteplase treatment within 45 minutes. Methods: Five hundred and eighty-six patients were treated with alteplase in our emergency departments (EDs) between January 2014 and October 2016; 368 patients were included for analysis. Multivariate regression analysis was used to assess the association between door-to-alteplase (DTA) times and 90-day modified Rankin scale (mRS) scores. Incidence of intracerebral hemorrhage (ICH) was also documented. Results: The median DTA time was 29 minutes versus 64 minutes in the DTA less than or equal to 45 minutes arm and more than 45 minutes arm, respectively. The primary outcome of 90-day mRS 0-1 was achieved in 56% of patients in the less than or equal to 45 minutes group versus 58% in more than 45 minutes group (P = .67). Odds of achieving mRS 0-1 were not significantly impacted by DTA times. In the multivariate regression analysis, patient characteristics associated with achieving mRS 0-1 were: younger age, male sex, not requiring intubation in the ED, and without prior history of hypertension, atrial fibrillation, or stroke. There was no significant difference in rates of ICH for patients less than or equal to 45 minutes versus more than 45 minutes. Conclusions: Rapid administration of alteplase was not associated with significantly better outcomes nor increased risk of ICH. Conclusions about efficacy are limited due to the retrospective nature of the study, small sample size, and incomplete data points.

Recurrent hemorrhages, new data, new decisions

The incidence and prevalence of spontaneous intracerebral haemorrhage (ICH) continues to increase worldwide. ICH is associated with high mortality (1 year and 5 year survival estimated at 46% and 29% respectively), and data on subsequent stroke events in ICH survivors are limited. This leads to management dilemmas in patients who are at risk of ischaemic vascular events (involving the brain, heart or peripheral vasculature) or thromboembolic disease, and who may benefit from treatment with antiplatelet or anticoagulant medications. Assessment of the prognosis for these serious vascular events is crucial to make informed management decisions after ICH. Features which may help identify a higher risk of subsequent stroke events include: ICH location (lobar ICH, which, in some cases, is associated with cerebral amyloid angiopathy [CAA]) has a higher recurrent ICH rate, while deep ICH, associated with hypertensive arteriopathy has a lower recurrent ICH risk. Imaging biomarkers of cerebral small vessel disease including cerebral microbleeds, cortical superficial siderosis (which might also reflect the balance of CAA and hypertensive arteriopathy) also affect prognosis after ICH. Based on these data it has been suggested that, given their increased ICH risk, patients with lobar ICH or high-risk imaging biomarkers should not be offered antithrombotic therapy, even those with AF (which confers a particular high ischaemic stroke risk). However, some recent observational and randomised trial data challenge this assumption. This talk will review relevant data to guide the use of baseline ICH features can help assess prognosis to inform difficult clinical treatment decisions after ICH.

White matter hyperintensity burden in patients with ischemic stroke treated with thrombectomy.

To determine the influence of white matter hyperintensity (WMH) burden on functional outcome, rate of symptomatic intracerebral hemorrhage (sICH), and procedural success in patients with acute ischemic stroke (AIS) treated by mechanical thrombectomy (MT) with current stentriever/aspiration devices. Patients with AIS due to large vessel occlusion (LVO) from the Thrombectomie des Artères Cérébrales (THRACE) trial and prospective cohorts from 2 academic comprehensive stroke centers treated with MT were pooled and retrospectively analyzed. WMH volumes were obtained by semiautomated planimetric segmentation and tested in association with the rate of favorable outcome (90-day functional independence), substantial recanalization after MT, and sICH. A total of 496 participants were included between 2015 and 2018 (50% female, mean age 68.1 ± 15.0 years). Overall, 434 (88%) patients presented with detectable WMH (mean ± SD 4.93 ± 7.7). Patients demonstrated increasingly worse outcomes with increasing WMH volumes (odds ratio [aOR]1.05 per 1-cm3 increase for unfavorable outcome, 95% confidence interval [CI] 1.01-1.06, p = 0.014). Fifty-seven percent of patients in the first quartile of WMH volume vs 28% in the fourth quartile demonstrated favorable outcome (p < 0.001). WMH severity was not associated with sICH rate (aOR 0.99, 95% CI 0.93-1.04, p = 0.66), nor did it influence recanalization success (aOR 0.99, 95% CI 0.96-1.02, p = 0.84). Our study provides evidence that in patients with AIS due to LVO and high burden of WMH as assessed by pretreatment MRI, the safety and efficacy profiles of MT are similar to those in patients with lower WMH burden and confirms that they are at higher risk of unfavorable outcome. Because more than a quarter of patients in the highest WMH quartile experienced favorable 3 months outcome, WMH burden may not be a good argument to deny MT. NCT01062698.

Stroke Care and Application of Thrombolysis in Ibero-America: Report From the SITS-SIECV Ibero-American Stroke Register

Standardized registries may provide valuable data to further improve stroke care. Our aim was to obtain updated information about characteristics of stroke patients and management of stroke across the Ibero-American countries, using a common in-hospital registry (Safe Implementation of Treatments in Stroke–Sociedad Iberoamericana de Enfermedades Cerebrovasculares) as a basis for further quality improvement. Data for this study were entered into the Safe Implementation of Treatments in Stroke registry from September 2009 to December 2013 by 58 centers in 14 countries. Data included demographics, risk factors, onset-to-door time, National Institutes of Health Stroke Scale score, stroke subtype, ischemic stroke etiology, treatments, 3-month mortality, and modified Rankin Scale score. Time to treatment was also recorded for patients treated with thrombolysis. Five thousand four hundred one patients were registered; median age, 65 years; 46% women; 3915 (72.5%) ischemic strokes; 686 (13.7%) hemorrhagic strokes; 213 (4.3%) subarachnoid hemorrhages; 414 (8.3%) transient ischemic attacks; and 31 (0.6%) cerebral vein thrombosis. The most prevalent risk factors were hypertension (71.3%), dyslipidemia (35.2%), and diabetes mellitus (23.6%). Atrial fibrillation was present in 15.1%. Three hundred one ischemic strokes were treated with intravenous thrombolysis (IVT; 7.7%). Patients undergoing IVT were more severely affected (median baseline National Institutes of Health Stroke Scale score, 11 versus 6). The rate of symptomatic intracerebral hemorrhages after IVT was 5.7%. At 3 months, 60.3% of IVT-treated patients and 59.1% of untreated patients were independent (modified Rankin Scale score, 0–2). Mortality was 11.4% in treated and 12.8% in untreated patients. Safe Implementation of Treatments in Stroke–Sociedad Iberoamericana de Enfermedades Cerebrovasculares is the largest registry of a general stroke population and the first study to evaluate the level of IVT use in Ibero-America. It provides valuable information that may help to improve the quality of stroke care in the Ibero-American region.

Risk of Intracerebral Hemorrhage and Mortality After Convexity Subarachnoid Hemorrhage in Cerebral Amyloid Angiopathy.

Background and Purpose- Convexity subarachnoid hemorrhage (cSAH) is an increasingly recognized presentation of cerebral amyloid angiopathy (CAA), usually revealed by transient symptoms, but data on its outcome are limited. We compared the risk of future intracerebral hemorrhage (ICH), cSAH, and death in patients with CAA after cSAH and after lobar ICH. Methods- Consecutive patients with probable CAA, based on the Boston criteria, presenting with cSAH (CAA-cSAH) or lobar ICH (CAA-ICH) were included. We obtained baseline clinical and magnetic resonance imaging data and follow-up information. Univariable and multivariable analyses were used to compare incidence rate for symptomatic ICH, symptomatic cSAH, and late-death (beyond 30 days) between patients with CAA-cSAH and CAA-ICH. Results- Among 105 patients (mean age, 76.7±7.5 years) enrolled, 44 participants presented with CAA-cSAH and 61 with CAA-ICH. The median follow-up was 22.2 months (interquartile range, 12.6-34.4). The symptomatic ICH rate (per person-year) was 10.5% (95% CI, 5.6-19.4) in patients with CAA-cSAH compared with 8.5% (95% CI, 4.4-16.4) in those with CAA-ICH (adjusted hazard ratio, 1.05; 95% CI, 0.32-3.43). The annual incidence rates of symptomatic cSAH (9.9% versus 3.8%; adjusted hazard ratio, 1.77; 95% CI, 0.43-7.28) and death (9.5% versus 17.8%; adjusted hazard ratio, 0.56; 95% CI, 0.22-1.43) were not significantly different between patients with CAA-cSAH and those with CAA-ICH. Conclusions- Patients with CAA-related cSAH have a poor outcome, with similar high risk of future ICH and long-term mortality than CAA patients after lobar ICH. Our findings may have important prognostic implication and guide management of patients with cSAH in CAA.

Association of Baseline Hyperglycemia With Outcomes of Patients With and Without Diabetes With Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Propensity Score-Matched Analysis From the SITS-ISTR Registry.

Available data from observational studies on the association of admission hyperglycemia (aHG) with outcomes of patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT) are contradictory, especially when stratified by diabetes mellitus (DM) history. We assessed the association of aHG (≥144 mg/dL) with outcomes stratified by DM history using propensity score-matched (PSM) data from the SITS-ISTR. The primary safety outcome was symptomatic intracranial hemorrhage (SICH); 3-month functional independence (FI) (modified Rankin Scale [mRS] scores 0-2) represented the primary efficacy outcome. Patients with and without aHG did not differ in baseline characteristics both in the non-DM (n = 12,318) and DM (n = 6,572) PSM subgroups. In the non-DM group, patients with aHG had lower 3-month FI rates (53.3% vs. 57.9%, P < 0.001), higher 3-month mortality rates (19.2% vs. 16.0%, P < 0.001), and similar symptomatic intracerebral hemorrhage (SICH) rates (1.7% vs. 1.8%, P = 0.563) compared with patients without aHG. Similarly, in the DM group, patients with aHG had lower rates of 3-month favorable functional outcome (mRS scores 0-1, 34.1% vs. 39.3%, P < 0.001) and FI (48.2% vs. 52.5%, P < 0.001), higher 3-month mortality rates (23.7% vs. 19.9%, P < 0.001), and similar SICH rates (2.2% vs. 2.7%, P = 0.224) compared with patients without aHG. In conclusion, aHG was associated with unfavorable 3-month clinical outcomes in patients with and without DM and AIS treated with IVT.

Emergent Carotid Stenting Plus Thrombectomy After Thrombolysis in Tandem Strokes: Analysis of the TITAN Registry.

Emergent carotid artery stenting plus mechanical thrombectomy is an effective treatment for acute ischemic stroke patients with tandem occlusion of the anterior circulation. However, there is limited data supporting the safety of this approach in patients treated with prior intravenous thrombolysis (IVT). We aimed to investigate the safety of emergent carotid artery stenting-mechanical thrombectomy approach in stroke patient population treated with prior IVT —We assessed patients with acute ischemic stroke because of atherosclerotic tandem occlusion that were treated with emergent carotid artery stenting-mechanical thrombectomy approach from the multicenter observational Thrombectomy in Tandem Lesions registry. Patients were divided into 2 groups based on pretreatment IVT (IVT versus no-IVT). Intracerebral hemorrhages were classified according to the European Cooperative Acute Stroke Study II criteria. Among 205 patients included in the present study, 125 (60%) received prior IVT. Time from symptoms onsetto-groin puncture was shorter (234±100 versus 256±234 minutes; P=0.002), and heparin use was less in the IVT group (14% versus 35%; P<0.001); otherwise, there was no difference in the baseline characteristics. There was no significant difference between the IVT and no-IVT groups in the rate of symptomatic intracerebral hemorrhage (5% versus 8%; P=0.544), parenchymal hematoma type 1 to 2 (15% versus 18%; P=0.647), successful reperfusion (modified Thrombolysis in Cerebral Ischemia 2b–3), or 90-day favorable outcome (modified Rankin Scale score of 0–2 at 90 days). The 90-day all-cause mortality rate was significantly lower in the IVT group (8% versus 20%; P=0.017). After adjusting for covariates, IVT was not associated with symptomatic intracerebral hemorrhage or 90-day mortality Emergent carotid artery stenting-mechanical thrombectomy approach was not associated with an increased risk of hemorrhagic complications in tandem occlusion patients who received IVT before the intervention.

Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data

Stroke thrombolysis with alteplase is currently recommended 0-4·5 h after stroke onset. We aimed to determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4·5 h or more from stroke onset or with symptoms on waking who might benefit from thrombolysis. In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous systematic review of thrombolysis and searched ClinicalTrials.gov for interventional studies of ischaemic stroke. Studies of alteplase versus placebo in patients (aged ≥18 years) with ischaemic stroke treated more than 4·5 h after onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0-1) at 3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036. We identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 3 months (adjusted odds ratio [OR] 1·86, 95% CI 1·15-2·99, p=0·011). Symptomatic intracerebral haemorrhage was more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [<1%] of 201 patients in the placebo group; adjusted OR 9·7, 95% CI 1·23-76·55, p=0·031). 29 (14%) of 213 patients in the alteplase group and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1·55, 0·81-2·96, p=0·66). Patients with ischaemic stroke 4·5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net benefit of thrombolysis. None.

Editors' note: DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial

In “DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial,” Barbe et al. compared deep brain stimulation (DBS) of the posterior subthalamic area (PSA) to DBS of the ventral intermediate nucleus of the thalamus (VIM) in patients with essential tremor (ET). They found that PSA-DBS is at least equally effective as, but possibly more efficient than, VIM-DBS and that there are no notable differences in side effects between stimulation at the 2 sites. Dr. Sidiropoulos describes the study as “elegant,” but notes the following concerns: (1) differences in spacing of the leads may have affected activation of the intended targets; (2) the type of lead used should have been provided, particularly because—in contrast to Boston Scientific leads—Medtronic leads have only a single current source; (3) lower pulse widths should have been explored with the Boston Scientific leads; (4) the rate of intracerebral hemorrhage (2/13 patients) is concerning and may be accounted for by technique limitations. In response, Barbe et al. acknowledge there may have been some current spread from the PSA to the VIM and vice versa. With respect to the rate of intracerebral hemorrhage, they postulated that the steepness of the surgical angle may have increased the risk of bleeding. Barbe et al. and Dr. Sidiropoulos agree that larger trials on this topic using tractographic data are needed. In “DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial,” Barbe et al. compared deep brain stimulation (DBS) of the posterior subthalamic area (PSA) to DBS of the ventral intermediate nucleus of the thalamus (VIM) in patients with essential tremor (ET). They found that PSA-DBS is at least equally effective as, but possibly more efficient than, VIM-DBS and that there are no notable differences in side effects between stimulation at the 2 sites. Dr. Sidiropoulos describes the study as “elegant,” but notes the following concerns: (1) differences in spacing of the leads may have affected activation of the intended targets; (2) the type of lead used should have been provided, particularly because—in contrast to Boston Scientific leads—Medtronic leads have only a single current source; (3) lower pulse widths should have been explored with the Boston Scientific leads; (4) the rate of intracerebral hemorrhage (2/13 patients) is concerning and may be accounted for by technique limitations.

Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues

As one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group. Several recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis. Nonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.

Direct Admission versus Secondary Transfer for Acute Stroke Patients Treated with Intravenous Thrombolysis and Thrombectomy: Insights from the Endovascular Treatment in Ischemic Stroke Registry

Background: To date, thrombectomy for large vessel occlusion (LVO) strokes can be performed only in comprehensive stroke centers with thrombectomy capacity. We compared the clinical outcome of patients first referred to a primary stroke center to those admitted directly to a comprehensive stroke center and treated on site in the multicentric observational Endovascular Treatment in Ischemic Stroke (ETIS) registry. Methods: From our perspective, multicenter, observational ETIS registry, we analyzed anterior circulation stroke patients, treated within 8 h, who underwent thrombectomy after thrombolysis and were admitted to a comprehensive stroke center either with drip and ship or mothership. Clinical and safety outcomes were compared between 2 groups. Results: A total of 971 patients were analyzed: 298 were treated with the mothership approach and 673 with drip and ship. Significantly more functional independence (90-day modified Rankin Scale [mRS] 0–2) was achieved in mothership (60.1%) than in drip and ship patients (52.6%; adjusted relative risk [RR] 0.87, 95% CI 0.77–0.98, p = 0.018). Excellent outcome (90-day mRS 0–1) was achieved in 45.3% of the mothership group, compared to 37.9% of the drip and ship group (RR 0.84, 95% CI 0.71–0.98; p = 0.026). According to the distance between the primary stroke center and the comprehensive stroke center, greater functional independence was achieved in mothership than in drip and ship >12.5 miles patients (adjusted RR 0.82; 95% CI 0.71–0.94). Results in the drip-ship group stratified according to time between cerebral imaging and groin puncture (categorized according to the median cut-off: 140 min) were similar. Symptomatic intracerebral hemorrhage rate and mortality within 90 days was similar in both groups (7.5 vs. 5.9%, p = 0.40; 17.4 vs. 16.1%, p = 0.63). Conclusions: Our study suggests that LVO stroke patients directly admitted to a comprehensive stroke center present a higher chance of functional independence, especially when the distance between the primary stroke center and comprehensive stroke center is >12.5 miles or when the time between cerebral imaging and groin puncture is ≥140 min.

Endovascular and Clinical Outcomes of Vertebrobasilar Intracranial Atherosclerosis-Related Large Vessel Occlusion.

Background and Purpose: Endovascular treatment (EVT) for acute vertebrobasilar intracranial atherosclerosis-related large vessel occlusion (ICAS-LVO) and its outcomes are not well known. We aimed to evaluate endovascular and clinical outcomes of vertebrobasilar ICAS-LVO patients who underwent EVT.Methods: Consecutive acute stroke patients who underwent EVT for vertebrobasilar LVO were retrospectively reviewed. Patients were assigned to the ICAS (+) or the ICAS (–) group based on angiographical findings. Procedural details and clinical outcomes were compared between the ICAS (+) and ICAS (–) groups.Results: This study included 77 patients with acute vertebrobasilar LVO who underwent EVT. Among the study subjects, 24 (31.2%) had an ICAS-LVO. Recanalization was achieved in 19 patients in the ICAS (+) group (79.2%), which was comparable with the ICAS (–) group (84.9%; p = 0.529). However, recanalization using conventional endovascular modalities (stent retriever thrombectomy, contact aspiration thrombectomy, or intra-arterial urokinase infusion) was less successful in the ICAS (+) group (36.8%) than the ICAS (–) group (100.0%; p < 0.001). All the remaining patients in the ICAS (+) group required specific rescue treatments appropriate for ICAS, including balloon angioplasty, stenting, or intra-arterial glycoprotein IIb/IIIa inhibitor infusion to obtain a successful recanalization. Procedural time was not significantly longer in the ICAS (+) group. The rates of favorable outcomes (37.5% vs. 41.5%; p = 0.740), death, and symptomatic intracerebral hemorrhage were not significantly different between the groups.Conclusion: ICAS-LVO was common in patients who underwent EVT for acute vertebrobasilar LVO. Although conventional modalities were often ineffective for vertebrobasilar ICAS-LVO, a comparable recanalization rate could be obtained with ICAS-specific modalities. Recanalization rate and procedural time were comparable, and clinical outcomes did not differ between patients with or without ICAS-LVO.

Hemorrhagic complications seen on immediate intraprocedural stereotactic computed tomography imaging during deep brain stimulation implantation

BackgroundWe present our operative experience of patients with movement disorders who developed intracerebral hemorrhage (ICH), which was identified on intraprocedural stereotactic computed tomography (CT) imaging performed immediately after deep brain stimulation (DBS) lead placement and prior to the implantation of further components of the DBS hardware. MethodsPatients who underwent DBS lead implantation from January 2009 through December 2017 were included in the present study. Most of the surgeries were performed in a staged fashion. All patients were operated using identical surgical and intraprocedural imaging techniques, and no microelectrode recordings were done. Leksell Stereotactic G frame and neuronavigation software was utilized for all surgeries. Intraprocedural stereotactic CT was performed to confirm the precise position of the implanted DBS lead and to rule out any hemorrhagic complications. ResultsOverall, 222 patients underwent 322 DBS lead implantations during 316 stereotactic procedures. Six patients exhibited early ICH recognized on intraprocedural stereotactic CT performed immediately after DBS lead placement; in addition, two patients developed delayed ICH due to large venous infarction. Four patients with ICH were asymptomatic. The ICH rate was 2.5% per electrode and 3.6% per patient; the permanent deficit rate was 1.2% per electrode and 1.8% per patient. The death rate due to ICH in our cohort was 0.6% per electrode and 0.9% per patient. ConclusionsIntraprocedural stereotactic CT can not only visualize the implanted DBS lead in the stereotactic space but also rule out early ICH. Identified predisposing factors for development of ICH include patient's age, hypertension, and previous antiplatelet therapy. Careful planning of stereotactic trajectories plays a paramount role in reducing the rate of ICH in DBS surgery.

Mechanical Thrombectomy in Ischemic Stroke Patients With Alberta Stroke Program Early Computed Tomography Score 0-5.

Background and Purpose- If anterior circulation large vessel occlusion acute ischemic stroke patients presenting with ASPECTS 0-5 (Alberta Stroke Program Early CT Score) should be treated with mechanical thrombectomy remains unclear. Purpose of this study was to report on the outcome of patients with ASPECTS 0-5 treated with mechanical thrombectomy and to provide data regarding the effect of successful reperfusion on clinical outcomes and safety measures in these patients. Methods- Multicenter, pooled analysis of 7 institutional prospective registries: Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the SOLITAIRE FR With the Intention for Thrombectomy (Clinical Trial Registration-URL: https://www.clinicaltrials.gov . Unique identifier: NCT03496064). Primary outcome was defined as modified Rankin Scale 0-3 at day 90 (favorable outcome). Secondary outcomes included rates of day 90 modified Rankin Scale 0-2 (functional independence), day 90 mortality and occurrence of symptomatic intracerebral hemorrhage. Multivariable logistic regression analyses were performed to assess the association of successful reperfusion with clinical outcomes. Outputs are displayed as adjusted Odds Ratios (aOR) and 95% CI. Results- Two hundred thirty-seven of 2046 patients included in this registry presented with anterior circulation large vessel occlusion and ASPECTS 0-5. In this subgroup, the overall rates of favorable outcome and mortality at day 90 were 40.1% and 40.9%. Achieving successful reperfusion was independently associated with favorable outcome (aOR, 5.534; 95% CI, 2.363-12.961), functional independence (aOR, 5.583; 95% CI, 1.964-15.873), reduced mortality (aOR, 0.180; 95% CI, 0.083-0.390), and lower rates of symptomatic intracerebral hemorrhage (aOR, 0.235; 95% CI, 0.062-0.887). The mortality-reducing effect remained in patients with ASPECTS 0-4 (aOR, 0.167; 95% CI, 0.056-0.499). Sensitivity analyses did not change the primary results. Conclusions- In patients presenting with ASPECTS 0-5, who were treated with mechanical thrombectomy, successful reperfusion was beneficial without increasing the risk of symptomatic intracerebral hemorrhage. Although the results do not allow for general treatment recommendations, formal testing of mechanical thrombectomy versus best medical treatment in these patients in a randomized controlled trial is warranted.

The risk of ventricular catheter misplacement and intracerebral hemorrhage in shunt surgery for hydrocephalus

Abstract Ventricular shunt insertion is a commonly performed neurosurgical procedure but few studies evaluate the rates of ventricular catheter (VC) misplacement and postoperative intracerebral hemorrhage (ICH) after shunt surgery. In this study, we evaluated the rate of VC misplacement and ICH after shunt insertion in hydrocephalus patients. A consecutive series of adult patients (n = 240) that received a ventricular shunt for hydrocephalus were included in the study. Misplacement was defined as tip of the VC located in the contralateral ventricle or intraparenchymal. The event of ICH was based on verification of intraparenchymal blood on an early ( Misplacement of the VC tip was found in 76 patients (33%); 70 patients with the VC tip in the contralateral ventricle and six patients (3%) with the VC tip intraparenchymal. ICH occurred in 8% of the patients. The shunt revision rate for accurately placed VCs was 17% compared to 21% for misplaced VC (p = 0.37). Proximal shunt failure occurred in 11% of the patients with VC misplacement compared to 5% of the patients with accurate VC placement (p = 0.07). VC misplacement occurred in one third and ICH was evident in 8% of the patients. However, VC misplacement did not significantly increase the shunt revision rate. Still, measures to optimize VC placement may be important to reduce risks following ventricular shunt placement.

Using machine learning to optimize selection of elderly patients for endovascular thrombectomy

BackgroundEndovascular thrombectomy (ET) is the standard of care for treatment of acute ischemic stroke (AIS) secondary to large vessel occlusion. The elderly population has been under-represented in clinical trials on...

Abstract 13: Risk of Intracerebral Hemorrhage in Pregnancy and the Postpartum Period: A Population Based Analysis using a Cohort-Cross Over Design

Introduction: While there is a documented increased risk of thrombotic events; little is known regarding the risk of intracerebral hemorrhage (ICH) during pregnancy / postpartum period (PP). We explore the risk of ICH in PP utilizing a cohort crossover design in which patients serve as their own control. Methods: We utilized State Inpatient Databases for NY, FL (2005 - 2014) and CA (2005 - 2011), and identified patients with labor/delivery diagnoses using validated ICD-9 codes. The cohort crossover design included a 64wk case period (40wk pregnancy/labor/delivery, 24wk postpartum), followed by a 52wk interim period, and a 64wk crossover period. We excluded patients who were ≤ 12yr, missing linkage information, admitted for false labor, or had a prior ICH. Subsequent pregnancies were not included. We compared the rate of ICH during case and crossover periods and report absolute risk difference and rate ratio with 95% confidence interval (CI) estimated using conditional Poisson regression. Results: Over 3.3 million deliveries were identified, with 238 patients experiencing ICH during the case period. Those who died during the case / interim period or were in PP during the crossover period were removed from analyses. The overall rate of ICH during case vs. crossover period was 8.1 vs 2.5 per 100,000 deliveries / patients, resulting in an absolute risk difference and rate ratio (CI) of 5.5 (4.3 - 6.8) and 3.2 (2.4 - 4.2) respectively. During the case period, the majority of ICH occurred during the 3 rd trimester and the first 12wks postpartum (Figure). Patients experiencing ICH during PP were more likely to be Black or Asian (compared to White), and had a history of hypertension, diabetes, coagulopathy, thrombocytopenia, or substance abuse (Table). Conclusion: Pregnancy confers a significantly higher risk of ICH that peaks during the 3 rd trimester and continues into early postpartum. Further investigation is warranted to characterize individuals at a greater risk of ICH during PP.

Abstract 109: Thrombectomy is Safe for Dawn- and Defuse-3-Ineligible Patients Who Present Within the Extended Window: A Subgroup Analysis From the BEST Prospective Cohort Study

Background: Recent data have demonstrated robust efficacy for endovascular thrombectomy in acute large vessel occlusion (LVO) up to 24h after symptom onset. Given the overwhelming benefit of this intervention in a highly selective, clinical trial population, it is plausible that a benefit may also be observed in some trial-ineligible patients. Methods: Using the BEST multi-center prospective cohort of consecutive patients who underwent thrombectomy for LVO, we compared DAWN and DEFUSE 3 trial-ineligible patients treated within 6-24 hours after last known normal (LKN) to trial-eligible patients, and to untreated controls from those trials. The co-primary outcomes were an early therapeutic response (decrease in NIHSS ≥10, or NIHSS 0-1 by 24h) and good functional outcome (90-day mRS 0-2). Secondary outcomes included change in NIHSS at 24h, intracerebral hemorrhage within 72h, and discharge to home or acute rehab. Results: Of 443 patients in the BEST cohort, 159 (36%) underwent endovascular therapy between 6-24 hours after LKN, of whom 71 (45%) were trial-ineligible. The most common trial exclusion criteria were M2 (53%) and multivessel occlusions (30%). Compared to trial-eligible patients, trial-ineligible patients were younger (median 63 vs. 72y, p=0.02) but had similar baseline NIHSS (median 14 vs. 15, p=0.28), ASPECTS scores (median 8 v. 8, p=0.69), times to recanalization (median 627 vs. 682 min, p=0.08), and rates of successful recanalization (TICI 2b/3, 83% v. 86%, p=0.57). Compared to DAWN untreated controls, BEST trial-ineligible patients were more likely to have an early therapeutic response (OR 2.02, 95%CI 1.00-4.06, p=0.049) and good functional outcome (OR 3.02, 95%CI 1.33-6.86, p=0.001). Compared to trial-eligible patients in BEST, trial-ineligible patients had similar improvements in 24h NIHSS (-2 vs. -4, p=0.33), rates of intracerebral hemorrhage (28% vs. 24%, p=0.54), and rates of discharge to home or rehab (77% vs. 73%, p=0.49). Conclusion: This multicenter prospective cohort demonstrates that thrombectomy for acute LVO within 24 hours in DAWN and DEFUSE 3 trial-ineligible patients is safe and may be effective. Treating these patients may be reasonable but our findings should be confirmed by additional randomized data trials.

Abstract WP445: Characteristics of Methamphetamine-Related Intracerebral Hemorrhage and Factors Associated With Outcomes

Background and Purposes: Methamphetamine use is on the rise worldwide. There are limited data and cognizance on methamphetamine-related intracerebral hemorrhage (ICH). This study aimed to investigate the characteristics of methamphetamine-related ICH and to explore the factors associated with outcomes. Methods: This retrospective cohort study enrolled consecutive ICH patients at a comprehensive stroke center between January 2011 and December 2017. Patients with methamphetamine related ICH were included for analysis of demographics, clinical features, and outcomes at hospital discharge. Factors associated with discharge outcomes were explored using multivariate logistic regression models. Results: Among the 686 consecutive patients admitted for spontaneous ICH during the study period, 412 (60.1%) had urine toxicology tests and 60 (8.7%) were identified to have methamphetamine use per history and positive urine test. Of note, 30 patients who denied substance use had positive urine test. The mean age was 51.8 years old and 78.3% patients were male. There was significant racial disparity in methamphetamine use, with highest ratio in Hispanics (14.9%), followed by White (9.2%), African Americans (5.7%), and Asians (1.2%). The mortality rate of methamphetamine-related ICH was 18.3% and only 25.0% patients achieved functional independence at hospital discharge. NIHSS (OR=0.15; 95% CI 0.04-0.62; P=0.005), GCS (OR=0.05; 95% CI 0.01-0.43; P=0.001), ICH score (OR=0.08; 95% CI 0.01-0.67; P=0.005), smoking history (OR=6.76; 95% CI 1.82-25.00; P=0.002), surgical intervention (OR=0.13; 95% CI 0.03-0.66; P=0.007) and ventilator support (OR=0.11; 95% CI 0.02-0.56; P=0.003) were independently associated with functional status. Risk factors of mortality include NIHSS (OR=2.45; 95% CI 1.75-3.44; P&lt;0.001), GCS (OR=3.06; 95% CI 2.05-4.59; P&lt;0.001), ICH score (OR=4.46; 95% CI 2.65-7.52; P&lt;0.001), creatinine level (OR=8.97; 95% CI 2.12-37.98; P=0.001) and ventilator support (OR=2.89; 95% CI 1.96-4.24; P&lt;0.001). Conclusion: Methamphetamine use is a major cause of ICH, especially in Hispanic population. Clinical severity scores, elevated creatinine levels, and ventilator support are associated with poor outcomes at hospital discharge.